For the first time, our results demonstrated that the CCL18 blockade could significantly prevent ESCC progression, indicating that inhibition of CCL18 could be a novel strategy for the treatment of ESCC. The gene discussed is CCL18; the disease is esophageal squamous cell carcinoma.